Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.33
+0.63004.96%
Post-market: 13.330.00000.00%16:38 EDT
Volume:867.89K
Turnover:11.65M
Market Cap:736.41M
PE:-4.83
High:13.85
Open:12.70
Low:12.55
Close:12.70
52wk High:16.93
52wk Low:6.96
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.74
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.81
PE(LYR):-5.51

Loading ...

4D Molecular Therapeutics CEO David Kirn Disposes of USD 754,632 in Common Shares

Reuters
·
Oct 08

4D Molecular Therapeutics is Maintained at Buy by Chardan Capital

Dow Jones
·
Oct 06

4D Molecular Therapeutics to Host Investor Day Webcast

Reuters
·
Oct 05

4D Molecular Therapeutics Price Target Raised to $33.00/Share from $29.00 by B of a Securities

Dow Jones
·
Sep 29

4D Molecular price target raised to $33 from $29 at BofA

TIPRANKS
·
Sep 29

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

TIPRANKS
·
Sep 29

Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results

TIPRANKS
·
Sep 28

4D Molecular Therapeutics Enrolls First Patients in Phase 3 4sight Trial of 4D-150 for Diabetic Macular Edema

Reuters
·
Sep 28

4Dmt Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4Sight in Dme

THOMSON REUTERS
·
Sep 28

4D Molecular Therapeutics - First Patients Enrolled in 4Sight Phase 3 Trial for 4D-150 in Dme

THOMSON REUTERS
·
Sep 28

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 22,317.75 in Common Shares

Reuters
·
Sep 23

4D Molecular Therapeutics CEO David Kirn Disposes of 58,333 Common Shares Worth $810,105.1

Reuters
·
Sep 17

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

MT Newswires Live
·
Sep 14

4D Molecular Therapeutics Price Target Announced at $20.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 14

4D Molecular Therapeutics Grants 96,000 Inducement RSUs to Seven New Employees

Reuters
·
Sep 12

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 584 Common Shares for $8,176

Reuters
·
Sep 04

4D Molecular Therapeutics to Present at Wells Fargo, Cantor, Morgan Stanley Healthcare Investor Conferences

Reuters
·
Aug 25

4D Molecular Therapeutics CEO David Kirn Disposes of Common Shares Worth $1,068,651.63

Reuters
·
Aug 22

4D Molecular Therapeutics Posts Corporate Presentation Highlighting AAV Gene Therapy Pipeline Led by 4D-150 for Wet AMD, DME

Reuters
·
Aug 21

4D Molecular Therapeutics CLO Scott Bizily Disposes of Common Shares Worth $39,567.5

Reuters
·
Aug 18